Merck to Inject €23 Million into Kansas, USA Facility for Cell Culture Media Production Expansion
Introduction:
Merck Designates Lenexa, Kansas Facility as North America's Largest Dry Powder Cell Culture Media Site and Center of Excellence.
Features:
Addition of 9,100 sq. m2 lab space and production capacity for cell culture media.
The investment will result in the creation of 60 job opportunities in the Kansas City area.
Expansion aligns with strategy to enhance supply chain for cell culture media and meet growing demand for therapies like vaccines and gene therapy.
The Lenexa facility is transformed into Merck's leading dry powder cell culture media site and Center of Excellence across North America.
Cell culture media crucial for manufacturing life-saving treatments, vaccines, gene therapy, and monoclonal antibodies.
New dry powder media manufacturing lines in Lenexa and Nantong, China, sites to boost global production capacity and ensure supply for future demand.
Specifications:
Name: Merck
Type: Expansion
